MEGAN PASSE: Open Payments
NPI 1396895579 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,126 in 206 payments from 16 companies in 2025. Trend: 2023 $3,633 · 2024 $5,011 · 2025 $4,126
Food & beverage: $3,981Education: $145
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 57 | $939 |
| ABBVIE INC. | 59 | $794 |
| Amgen Inc. | 16 | $686 |
| UCB, Inc. | 26 | $554 |
| Novartis Pharmaceuticals Corporation | 20 | $487 |
| Lilly USA, LLC | 7 | $139 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $114 |
| AstraZeneca Pharmaceuticals LP | 2 | $107 |
| E.R. Squibb & Sons, L.L.C. | 3 | $86 |
| Aurinia Pharma U.S., Inc. | 3 | $56 |
Products named: TREMFYA, Bimzelx, COSENTYX, RINVOQ, SKYRIZI, TAVNEOS, EVENITY, TALTZ.
Industry payments across TX — which companies pay providers there.
